RecruitingNCT06439992

Beta Amyloid PET Imaging for Alzheimer Disease With [18F]-Fluselenamyl

Studying Amyloidosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Washington University School of Medicine
Principal Investigator
Tammie Benzinger, MD., PhD, M.D
Washington University School of Medicine
Intervention
18F-Fluselenamyl(drug)
Enrollment
60 enrolled
Eligibility
18 years · All sexes
Timeline
20232026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06439992 on ClinicalTrials.gov

Other trials for Amyloidosis

Additional recruiting or active studies for the same condition.

See all trials for Amyloidosis

← Back to all trials